$198.57
1.50% today
Nasdaq, Sep 16, 08:45 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock price

$195.63
-8.42 4.13% 1M
-30.93 13.65% 6M
-63.14 24.40% YTD
-60.28 23.56% 1Y
-106.31 35.21% 3Y
-41.00 17.33% 5Y
-99.23 33.65% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
-2.26 1.14%
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Key metrics

Market capitalization $28.50b
Enterprise Value $33.44b
P/E (TTM) P/E ratio 24.64
EV/FCF (TTM) EV/FCF 21.37
EV/Sales (TTM) EV/Sales 3.60
P/S ratio (TTM) P/S ratio 3.07
P/B ratio (TTM) P/B ratio 1.79
Revenue growth (TTM) Revenue growth -1.91%
Revenue (TTM) Revenue $9.29b
EBIT (operating result TTM) EBIT $1.81b
Free Cash Flow (TTM) Free Cash Flow $1.57b
Cash position $1.91b
EPS (TTM) EPS $7.94
P/E forward 15.70
P/S forward 2.96
EV/Sales forward 3.47
Short interest 2.59%
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Analyst Opinions

35 Analysts have issued a Biogen forecast:

24x Buy
69%
11x Hold
31%

Analyst Opinions

35 Analysts have issued a Biogen forecast:

Buy
69%
Hold
31%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
9,288 9,288
2% 2%
100%
- Direct Costs 2,938 2,938
2% 2%
32%
6,350 6,350
4% 4%
68%
- Selling and Administrative Expenses 1,961 1,961
11% 11%
21%
- Research and Development Expense 2,005 2,005
2% 2%
22%
2,385 2,385
14% 14%
26%
- Depreciation and Amortization 572 572
3% 3%
6%
EBIT (Operating Income) EBIT 1,813 1,813
17% 17%
20%
Net Profit 1,159 1,159
57% 57%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
GlobeNewsWire
4 days ago
Despite favorable views on litifilimab, AbbVie's Rinvoq and BMS' Sotyktu capture the most prescriber interest for approval, according to Spherix Global Insights. Despite favorable views on litifilimab, AbbVie's Rinvoq and BMS' Sotyktu capture the most prescriber interest for approval, according to Spherix Global Insights.
Positive
Barrons
4 days ago
Money has poured into the sector as markets have grown concerned about the economy.
Neutral
GlobeNewsWire
4 days ago
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,570
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today